AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

The stock's fall snapped a two-day winning streak.

According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...

On CNBC's “Halftime Report Final Trades,” Stephen L. Weiss of Short Hills Capital Partners recommended buying TransDigm Group ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

This Elliott Wave analysis for AbbVie Inc. (ABBV), breaks down the stock’s current price action using Elliott Wave Theory, providing traders with insights into possible opportunities. We’ll explore ...

Vysis, Inc., a leading genomic disease management ... Abbott created the Established Pharmaceuticals Division in 2010. The creation of AbbVie In 2011, Abbott announced it was to separate into ...